Does bivalirudin started during transport improve 30-day clinical outcomes in patients undergoing primary PCI?
Pre-hospital administration of bivalirudin for primary PCI improves 30-day outcomes and reduces bleeding, but increases the risk of acute stent thrombosis.
Bivalirudin, started during transport for primary PCI, improved 30-day clinical outcomes with a reduction in major bleeding but with an increase in acute stent thrombosis. (Funded by the Medicines Company; EUROMAX ClinicalTrials.gov number, NCT01087723.).
Steg et al. (Wed,) studied this question.